Meeting Our Commitments as a Responsible Manufacturer of Antibiotics

Responsible antibiotic manufacturing practices are part of Pfizer's Pharmaceuticals in the Environment (PiE) Program. In 2018, our PiE program continued to focus on wastewaters from antibiotic manufacturing operations through the completion of environmental risk assessments (ERAs). ERAs have been completed for all internal antibiotic manufacturing sites and all external suppliers in India and China; assessments are underway for all other antibiotic suppliers globally. As a result, Pfizer has enhanced, and continues to enhance, operational practices at both our own and supplier facilities. At some locations, further assessment, including sampling, is underway. In 2018, we also partnered with technical consultants to explore additional antibiotic wastewater treatment options. This year, Pfizer also continued our leading role as part of the Antimicrobial Resistance (AMR) Industry Alliance manufacturing group (the Alliance Manufacturing Group). Refer to the infographic below for progress made in 2018 with respect to AMR Industry Alliance commitments. To learn more about Pfizer's policy position on AMR, including antibiotic manufacturing, refer to here, and to learn more about the AMR Industry Alliance related to manufacturing and the environment please click here.

In 2018, we made the following progress against the AMR Roadmap commitments:

	Commitment	Review our manufacturing and supply chains to assess good practices in managing the release of antibiotic discharge into the environment.
	Update	We completed environmental risk assessment of antibiotic discharges at our Pfizer-owned and -operated manufacturing sites, and at our antibiotic suppliers in India and China, and commenced assessments at our antibiotic suppliers in the rest of the world. The assessments conducted to date indicate good practices are being followed at many sites. In some cases, action plans have been developed to improve discharge controls; at other locations, further assessment, including sampling, is underway.
	Commitment	Establish a common framework for managing antibiotic discharge, building on existing work such as the Pharmaceutical Supply Chain Initiative (PSCI), and apply these principles across our own internal manufacturing and external supply chain by 2018.
	Update	Pfizer evaluated our environmental programs that apply to sites and to suppliers against the AMR Industry Alliance's "Common Antibiotic Manufacturing framework." Existing Pfizer policies and procedures largely met the expectations within the framework, and areas not fully aligned were modified. Additionally, audit protocols for evaluating performance against the common framework for internal and external sites were developed building on PSCI assessment criteria.
	Commitment	Work with stakeholders to develop a practical mechanism to transparently demonstrate that our supply chains meet the standards in the framework.
	Update	In 2018, Pfizer worked with the Alliance Manufacturing group to agree on metrics and key performance indicators (KPIs) to demonstrate performance against the standards within the common framework. In 2019, Pfizer will publish further performance information on www.pfizer.com.
	Commitment	Work with independent technical experts to establish science-driven, risk-based targets for discharge concentrations for antibiotics and good practice methods to reduce environmental impact of manufacturing discharges by 2020.
	Update	The Alliance Manufacturing Group, with support from Pfizer, published a list of antibiotic discharge targets for a range of antibiotic compounds.